{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T18:42:14Z","timestamp":1782672134574,"version":"3.54.5"},"reference-count":108,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","criticalcare.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Care Clinics"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ccc.2019.12.006","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T08:18:29Z","timestamp":1580977109000},"page":"357-377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Thrombotic Thrombocytopenic Purpura, Heparin-Induced Thrombocytopenia, and Disseminated Intravascular Coagulation"],"prefix":"10.1016","volume":"36","author":[{"given":"Ram","family":"Kalpatthi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E.","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/cc4975","article-title":"Coagulation abnormalities in critically ill patients","volume":"10","author":"Levi","year":"2006","journal-title":"Crit Care"},{"issue":"7","key":"10.1016\/j.ccc.2019.12.006_bib2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12630-013-9933-7","article-title":"Thrombocytopenia in the critically ill: prevalence, incidence, risk factors, and clinical outcomes","volume":"60","author":"Williamson","year":"2013","journal-title":"Can J Anaesth"},{"issue":"14","key":"10.1016\/j.ccc.2019.12.006_bib3","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa1014475","article-title":"Dalteparin versus unfractionated heparin in critically ill patients","volume":"364","author":"Cook","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib4","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1097\/00003246-200006000-00031","article-title":"Thrombocytopenia and prognosis in intensive care","volume":"28","author":"Vanderschueren","year":"2000","journal-title":"Crit Care Med"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib5","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1378\/chest.121.4.1262","article-title":"D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients","volume":"121","author":"Shorr","year":"2002","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.ccc.2019.12.006_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib7","first-page":"593","article-title":"Thrombotic thrombocytopenic purpura: from diagnosis to therapy","volume":"21","author":"Mariotte","year":"2015","journal-title":"Curr Opin Crit Care"},{"issue":"8","key":"10.1016\/j.ccc.2019.12.006_bib8","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ccc.2019.12.006_bib9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.ccc.2019.12.006_bib10","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","article-title":"Clinical practice. Thrombotic thrombocytopenic purpura","volume":"354","author":"George","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ccc.2019.12.006_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib12","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib13","doi-asserted-by":"crossref","first-page":"e33029","DOI":"10.1371\/journal.pone.0033029","article-title":"Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan","volume":"7","author":"Matsumoto","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.ccc.2019.12.006_bib14","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/imj.12935","article-title":"Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP\/thrombotic microangiopathy registry","volume":"46","author":"Blombery","year":"2016","journal-title":"Intern Med J"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and laboratory diagnosis of TTP: an integrated approach","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/asheducation-2018.1.539","article-title":"Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura","volume":"2018","author":"Dane","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ccc.2019.12.006_bib22","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/asheducation.V2012.1.610.3798654","article-title":"Role of ADAMTS13 in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura","volume":"2012","author":"Kremer Hovinga","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jca.21673","article-title":"Thrombotic thrombocytopenic purpura: a 5-year tertiary care centre experience","volume":"34","author":"Swart","year":"2019","journal-title":"J\u00a0Clin Apher"},{"issue":"3 Pt 2","key":"10.1016\/j.ccc.2019.12.006_bib24","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.lpm.2011.10.024","article-title":"Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura","volume":"41","author":"Coppo","year":"2012","journal-title":"Presse Med"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib25","doi-asserted-by":"crossref","first-page":"E73","DOI":"10.1002\/ajh.25002","article-title":"No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry","volume":"93","author":"Masias","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib26","first-page":"80","article-title":"Acute pancreatitis-induced thrombotic thrombocytopenic purpura","volume":"13","author":"Gurjar","year":"2012","journal-title":"JOP"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jca.21248","article-title":"Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency","volume":"27","author":"George","year":"2012","journal-title":"J\u00a0Clin Apher"},{"issue":"2","key":"10.1016\/j.ccc.2019.12.006_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib29","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment","volume":"16","author":"Li","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib31","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib33","first-page":"149","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: the seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J\u00a0Clin Apher"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib35","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib36","doi-asserted-by":"crossref","first-page":"E127","DOI":"10.1002\/ajh.23997","article-title":"Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? Experience of the French thrombotic microangiopathies reference center","volume":"90","author":"Benhamou","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.ccc.2019.12.006_bib37","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jth.13571","article-title":"Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"24","key":"10.1016\/j.ccc.2019.12.006_bib38","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.ccc.2019.12.006_bib41","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib42","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.ccc.2019.12.006_bib43","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","article-title":"Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens","volume":"1","author":"Westwood","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib44","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood.2019000954","article-title":"How targeted therapy disrupts the treatment paradigm for acquired TTP: the risks, benefits, and unknowns","volume":"134","author":"Mazepa","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ccc.2019.12.006_bib47","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1007\/s00134-019-05736-5","article-title":"Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura","volume":"45","author":"Azoulay","year":"2019","journal-title":"Intensive Care Med"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jth.12114","article-title":"Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse","volume":"11","author":"Westwood","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"10.1016\/j.ccc.2019.12.006_bib49","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1182\/blood-2008-02-078014","article-title":"Heparin-induced thrombocytopenia: a historical perspective","volume":"112","author":"Kelton","year":"2008","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib50","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V72.3.925.bloodjournal723925","article-title":"Heparin-induced thrombocytopenia: laboratory studies","volume":"72","author":"Kelton","year":"1988","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MOH.0b013e3283497ef2","article-title":"Recent advances in heparin-induced thrombocytopenia","volume":"18","author":"Cuker","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.ccc.2019.12.006_bib52","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/blood-2005-11-012450","article-title":"Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia","volume":"108","author":"Warkentin","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib53","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/TA.0000000000000952","article-title":"Body mass index strongly impacts the diagnosis and incidence of heparin-induced thrombocytopenia in the surgical intensive care unit","volume":"80","author":"Bloom","year":"2016","journal-title":"J\u00a0Trauma Acute Care Surg"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib54","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood.V96.5.1703","article-title":"Impact of the patient population on the risk for heparin-induced thrombocytopenia","volume":"96","author":"Warkentin","year":"2000","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ccc.2019.12.006_bib55","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2009-07-231506","article-title":"The severity of trauma determines the immune response to PF4\/heparin and the frequency of heparin-induced thrombocytopenia","volume":"115","author":"Lubenow","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib56","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1046\/j.1440-1754.2003.00139.x","article-title":"Heparin-induced thrombocytopenia in children","volume":"39","author":"Newall","year":"2003","journal-title":"J\u00a0Paediatr Child Health"},{"issue":"11","key":"10.1016\/j.ccc.2019.12.006_bib57","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood.V84.11.3691.bloodjournal84113691","article-title":"Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia","volume":"84","author":"Warkentin","year":"1994","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ccc.2019.12.006_bib58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM198703053161004","article-title":"Immune endothelial-cell injury in heparin-associated thrombocytopenia","volume":"316","author":"Cines","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.ccc.2019.12.006_bib59","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2010-03-276964","article-title":"Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia","volume":"116","author":"Rauova","year":"2010","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ccc.2019.12.006_bib60","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ajh.24759","article-title":"Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia","volume":"92","author":"Kuter","year":"2017","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib61","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(96)00258-6","article-title":"A\u00a014-year study of heparin-induced thrombocytopenia","volume":"101","author":"Warkentin","year":"1996","journal-title":"Am J Med"},{"issue":"20","key":"10.1016\/j.ccc.2019.12.006_bib62","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib63","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.chest.2017.11.039","article-title":"Heparin-induced thrombocytopenia in the critically ill patient","volume":"154","author":"East","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccc.2019.12.006_bib64","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1517\/14740330902778180","article-title":"Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes","volume":"8","author":"Warkentin","year":"2009","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"10.1016\/j.ccc.2019.12.006_bib65","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1111\/j.1538-7836.2010.03795.x","article-title":"Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia","volume":"8","author":"Schindewolf","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"10.1016\/j.ccc.2019.12.006_bib66","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1182\/blood-2011-02-335208","article-title":"Antibodies associated with heparin-induced thrombocytopenia (HIT) inhibit activated protein C generation: new insights into the prothrombotic nature of HIT","volume":"118","author":"Kowalska","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib67","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1538-7836.2006.01787.x","article-title":"Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings","volume":"4","author":"Lo","year":"2006","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccc.2019.12.006_bib68","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1182\/asheducation-2013.1.668","article-title":"Heparin-induced thrombocytopenia","volume":"2013","author":"Lee","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6\u20137","key":"10.1016\/j.ccc.2019.12.006_bib69","first-page":"563","article-title":"Heparin-induced thrombocytopenia: a frequent complication after cardiac surgery","volume":"100","author":"Pouplard","year":"2007","journal-title":"Arch Mal Coeur Vaiss"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib70","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.chest.2017.06.001","article-title":"A\u00a0platelet factor 4-dependent platelet activation assay facilitates early detection of pathogenic heparin-induced thrombocytopenia antibodies","volume":"152","author":"Jones","year":"2017","journal-title":"Chest"},{"issue":"14","key":"10.1016\/j.ccc.2019.12.006_bib71","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1161\/01.CIR.103.14.1838","article-title":"Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia","volume":"103","author":"Lewis","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.thromres.2005.04.011","article-title":"Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and\/or coumarin explain the rapid shift in clinical practice during the 1990s","volume":"117","author":"Lubenow","year":"2006","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.ccc.2019.12.006_bib73","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/j.1538-7836.2011.04487.x","article-title":"Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series","volume":"9","author":"Warkentin","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"issue":"21","key":"10.1016\/j.ccc.2019.12.006_bib74","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1016\/j.jacc.2017.09.1099","article-title":"Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia","volume":"70","author":"Schindewolf","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.thromres.2014.03.029","article-title":"Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study","volume":"134","author":"Schindewolf","year":"2014","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib76","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/jca.21709","article-title":"Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: results of an international practice survey","volume":"34","author":"Onwuemene","year":"2019","journal-title":"J\u00a0Clin Apher"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib77","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.chest.2017.03.050","article-title":"IVIg for treatment of severe refractory heparin-induced thrombocytopenia","volume":"152","author":"Padmanabhan","year":"2017","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib78","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.transci.2018.06.007","article-title":"Intravenous immunoglobulin as an adjunct therapy in persisting heparin-induced thrombocytopenia","volume":"57","author":"Park","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib79","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1055\/s-0037-1616068","article-title":"Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation","volume":"86","author":"Taylor","year":"2001","journal-title":"Thromb Haemost"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib80","first-page":"73","article-title":"Clinical aspects of DIC--disseminated intravascular coagulation","volume":"48","author":"Matsuda","year":"1996","journal-title":"Pol J Pharmacol"},{"issue":"9","key":"10.1016\/j.ccc.2019.12.006_bib81","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00134-005-2685-2","article-title":"Modified score for disseminated intravascular coagulation in the critically ill","volume":"31","author":"Sivula","year":"2005","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.ccc.2019.12.006_bib82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.CCM.0000196832.27501.B2","article-title":"New disseminated intravascular coagulation score: a useful tool to predict mortality in comparison with Acute Physiology and Chronic Health Evaluation II and Logistic Organ Dysfunction scores","volume":"34","author":"Angstwurm","year":"2006","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/00001721-200501000-00011","article-title":"Performance and prognostic importance of a new clinical and laboratory scoring system for identifying non-overt disseminated intravascular coagulation","volume":"16","author":"Toh","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib84","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1378\/chest.11-1197","article-title":"Epidemiology of critical care syndromes, organ failures, and life-support interventions in a suburban US community","volume":"140","author":"Cartin-Ceba","year":"2011","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.ccc.2019.12.006_bib85","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1097\/01.CCM.0000147769.07699.E3","article-title":"Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation","volume":"32","author":"Bakhtiari","year":"2004","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/01.CCM.0000295317.97245.2D","article-title":"Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey","volume":"36","author":"Gando","year":"2008","journal-title":"Crit Care Med"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib87","first-page":"1099","article-title":"Clinical course and outcome of disseminated intravascular coagulation diagnosed by Japanese Association for Acute Medicine criteria. Comparison between sepsis and trauma","volume":"100","author":"Kushimoto","year":"2008","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib88","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s11239-014-1068-3","article-title":"The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database","volume":"38","author":"Murata","year":"2014","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"5","key":"10.1016\/j.ccc.2019.12.006_bib89","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1378\/chest.12-2112","article-title":"Trends in the incidence and outcomes of disseminated intravascular coagulation in critically ill patients (2004-2010): a population-based study","volume":"143","author":"Singh","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ccc.2019.12.006_bib90","doi-asserted-by":"crossref","first-page":"16037","DOI":"10.1038\/nrdp.2016.37","article-title":"Disseminated intravascular coagulation","volume":"2","author":"Gando","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"10.1016\/j.ccc.2019.12.006_bib91","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJM199908193410807","article-title":"Disseminated intravascular coagulation","volume":"341","author":"Levi","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib92","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-2006-933340","article-title":"Tissue factor in trauma and organ dysfunction","volume":"32","author":"Gando","year":"2006","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib93","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/SLA.0b013e31821221b1","article-title":"Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature","volume":"254","author":"Gando","year":"2011","journal-title":"Ann Surg"},{"key":"10.1016\/j.ccc.2019.12.006_bib94","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cca.2014.04.020","article-title":"Disseminated intravascular coagulation: testing and diagnosis","volume":"436","author":"Wada","year":"2014","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib95","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1055\/s-0038-1649835","article-title":"Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group","volume":"74","author":"Wada","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ccc.2019.12.006_bib96","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.tmrv.2017.10.001","article-title":"Purpura fulminans: mechanism and management of dysregulated hemostasis","volume":"32","author":"Colling","year":"2018","journal-title":"Transfus Med Rev"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib97","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1055\/s-2007-1002683","article-title":"Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies","volume":"16","author":"Marlar","year":"1990","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"10.1016\/j.ccc.2019.12.006_bib98","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4103\/0019-509X.176731","article-title":"Clinico-hematological profile and outcome of acute promyelocytic leukemia patients at a tertiary care center in North India","volume":"52","author":"Dayama","year":"2015","journal-title":"Indian J Cancer"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib99","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B","article-title":"Acute promyelocytic leukemia in 57 previously untreated patients","volume":"55","author":"Cordonnier","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.ccc.2019.12.006_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12155","article-title":"Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines","author":"Wada","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ccc.2019.12.006_bib101","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1538-7836.2007.02297.x","article-title":"The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage","volume":"5","author":"Charbit","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.ccc.2019.12.006_bib102","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13054-016-1265-x","article-title":"The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition","volume":"20","author":"Rossaint","year":"2016","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.ccc.2019.12.006_bib103","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology","volume":"145","author":"Levi","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ccc.2019.12.006_bib104","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0049-3848(93)90109-2","article-title":"Clinical evaluation of low-molecular-weight heparin (FR-860) on disseminated intravascular coagulation (DIC)--a multicenter co-operative double-blind trial in comparison with heparin","volume":"72","author":"Sakuragawa","year":"1993","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.ccc.2019.12.006_bib105","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"de la Serna","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ccc.2019.12.006_bib106","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1046\/j.1365-2141.2000.02270-8.x","article-title":"All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia","volume":"110","author":"Brown","year":"2000","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.ccc.2019.12.006_bib107","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ccc.2019.12.006_bib108","article-title":"Antithrombin III for critically ill patients","author":"Allingstrup","year":"2016","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Critical Care Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070419301010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749070419301010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:06:08Z","timestamp":1760061968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749070419301010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":108,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0749070419301010"],"URL":"https:\/\/doi.org\/10.1016\/j.ccc.2019.12.006","relation":{},"ISSN":["0749-0704"],"issn-type":[{"value":"0749-0704","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic Thrombocytopenic Purpura, Heparin-Induced Thrombocytopenia, and Disseminated Intravascular Coagulation","name":"articletitle","label":"Article Title"},{"value":"Critical Care Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccc.2019.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}